Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bromocriptine mesylate
Drug ID BADD_D00305
Description Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.
Indications and Usage For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.
Marketing Status approved; investigational
ATC Code G02CB01; N04BC01
DrugBank ID DB01200
KEGG ID D00780
MeSH ID D001971
PubChem ID 31100
TTD Drug ID D06YFA
NDC Product Code 0574-0106; 55486-1561; 30698-201; 0781-5325; 0378-7096; 68012-258; 60687-286; 65841-654; 73212-035; 51927-2274; 30698-202; 68382-110
UNII FFP983J3OD
Synonyms Bromocriptine | 2-Bromo-alpha-ergokryptine | 2 Bromo alpha ergokryptine | Bromocryptin | 2-Bromoergokryptine | 2 Bromoergokryptine | Bromocriptin | 2-Bromoergocryptine | 2 Bromoergocryptine | 2-Bromo-alpha-ergocryptine | 2 Bromo alpha ergocryptine | CB-154 | CB 154 | CB154 | Parlodel | 2-Bromoergocryptine Mesylate | 2 Bromoergocryptine Mesylate | Mesylate, 2-Bromoergocryptine | Bromocriptine Mesylate | Mesylate, Bromocriptine | 2-Bromoergocryptine Methanesulfonate | 2 Bromoergocryptine Methanesulfonate | Methanesulfonate, 2-Bromoergocryptine
Chemical Information
Molecular Formula C33H44BrN5O8S
CAS Registry Number 22260-51-1
SMILES CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C 4)Br)C)O.CS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pericarditis constrictive02.06.02.002--Not Available
Peripheral coldness23.06.04.008; 24.04.03.006; 08.01.09.010--Not Available
Pleural disorder22.05.03.002--Not Available
Pleural effusion22.05.02.002--
Pleural fibrosis22.05.03.003--Not Available
Pleurisy22.05.01.001--Not Available
Pollakiuria20.02.02.007--
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.009--
Psychomotor hyperactivity19.11.02.003; 17.01.02.011--Not Available
Pulmonary fibrosis22.01.02.006--
Rash23.03.13.001--Not Available
Raynaud's phenomenon24.04.03.003--Not Available
Retroperitoneal fibrosis20.06.01.006; 10.02.01.026; 07.07.03.003--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Rhinorrhoea22.12.03.021--
Seizure17.12.03.001--
Sensory loss17.02.07.007--Not Available
Shock24.06.02.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Sleep disorder19.02.04.001--Not Available
Sluggishness08.01.01.004--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Status epilepticus17.12.03.005--Not Available
Superior sagittal sinus thrombosis24.01.04.004; 17.08.03.001--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Urinary incontinence17.05.01.008; 20.02.02.010--
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages